Kinaset Therapeutics to Share Outcomes from Frevecitinib Phase 1 Clinical Study
04 Sep 2024 //
BUSINESSWIRE
Kinaset Debuts Positive KN-002 Phase 1b Outcomes At ATS 2024
21 May 2024 //
BUSINESSWIRE
Kinaset to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
BUSINESSWIRE
Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes
07 Dec 2023 //
BUSINESSWIRE
Kinaset Therapeutics to Present at the ATS) 2023 Respiratory Innovation Summit
15 May 2023 //
BUSINESSWIRE
Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as CMO
07 Jul 2022 //
BUSINESSWIRE
Kinaset Announces Dosing in PIb Study of KN-002 in Volunteers and Patients
15 Sep 2021 //
BUSINESSWIRE